Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by narmacon Dec 21, 2022 2:49pm
138 Views
Post# 35185389

RE:RE:RE:RE:RE:RE:1.2 billion fully diluted shares but $50 billion...

RE:RE:RE:RE:RE:RE:1.2 billion fully diluted shares but $50 billion...This is actually a great deal,,,if,,,,,xB3 dont work,,,,it is an absolute embarrassment if it does! I bought the risk in the clinic,,not the risk from poor management!

We are said to have deals with payouts of upwards of $200 Million dollars,,,,,,was that not said!!!,,add up the present deals,,,,,,,shelve xB3 for data to come out,,,,,do a PP to pay off our debt,,,,,,wait it out for 2 more years with full control of our technology!! ,,,,,,and yet our management team is allowing us to go on the block for $4 million dollars?????,,,,,stop this insanity!!,,,,,lots of options left for BTI!!

Salterelli was so sub-dued on the webinar,,,,,he looked stunned ,,,probably shocked at the lack of ability and progress by the senior team.

Old west robbery!!!,,White collar crime!!!!,,,,,and us with a greater market cap by 50% becoming the least in proportion in Biodexa...and smaller than the entity buying us or merging us!! What worst taste in a shareholders mouth could one envision???

The only answer is a no vote. The retail shareholders will appoint new management and a new BoD for Bioasis.

A big fat..... NO,,,,,,,, will be in on proxyvote!!!


<< Previous
Bullboard Posts
Next >>